

Publications

1. [Prenatal diagnosis of Down syndrome: how best to deliver the news.](#) Skotko BG, Kishnani PS, Capone GT; Down Syndrome Diagnosis Study Group. *Am J Med Genet A*. 2009 Nov;149A(11):2361-7.
2. [Postnatal diagnosis of Down syndrome: synthesis of the evidence on how best to deliver the news.](#) Skotko BG, Capone GT, Kishnani PS; Down Syndrome Diagnosis Study Group. *Pediatrics*. 2009 Oct;124(4):e751-8. Review.
3. [The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome.](#) Kishnani PS, Sommer BR, Handen BL, Seltzer B, Capone GT, Spiridigliozzi GA, Heller JH, Richardson S, McRae T. *Am J Med Genet A*. 2009 Aug;149A(8):1641-54.
4. [Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series.](#) Spiridigliozzi GA, Heller JH, Crissman BG, Sullivan-Saarela JA, Eells R, Dawson D, Li J, Kishnani PS. *Am J Med Genet A*. 2007 Jul 1;143A(13):1408-13.
5. [Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study.](#) Heller JH, Spiridigliozzi GA, Crissman BG, Sullivan JA, Eells RL, Li JS, Doraiswamy PM, Krishnan KR, Kishnani PS. *J Child Adolesc Psychopharmacol*. 2006 Dec;16(6):755-65.
6. [Clinical manifestations of hematologic and oncologic disorders in patients with Down syndrome.](#) Dixon N, Kishnani PS, Zimmerman S. *Am J Med Genet C Semin Med Genet*. 2006 Aug 15;142C(3):149-57. Review.
7. [Clinical trials in children with Down syndrome: issues from a cognitive research perspective.](#) Heller JH, Spiridigliozzi GA, Crissman BG, Sullivan-Saarela JA, Li JS, Kishnani PS. *Am J Med Genet C Semin Med Genet*. 2006 Aug 15;142C(3):187-95. Review.
8. [Current perspectives on Down syndrome: selected medical and social issues.](#) Crissman BG, Worley G, Roizen N, Kishnani PS. *Am J Med Genet C Semin Med Genet*. 2006 Aug 15;142C(3):127-30. Review.
9. [Donepezil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial.](#) Heller JH, Spiridigliozzi GA, Doraiswamy PM, Sullivan JA, Crissman BG, Kishnani PS. *Am J Med Genet A*. 2004 Oct 15;130A(3):325-6.
10. [New onset focal weakness in children with Down syndrome.](#) Worley G, Shbarou R, Heffner AN, Belsito KM, Capone GT, Kishnani PS. *Am J Med Genet A*. 2004 Jul 1;128A(1):15-8.
11. [Donepezil use in Down syndrome.](#) Kishnani PS, Sullivan JA, Spiridigliozzi GA, Heller JH, Crissman BG. *Arch Neurol*. 2004 Apr;61(4):605-6.

12. [Hypothyroidism in Down syndrome: screening guidelines and testing methodology.](#) Hardy O, Worley G, Lee MM, Chaing S, Mackey J, Crissman B, Kishnani PS. Am J Med Genet A. 2004 Feb 1;124A(4):436-7.
13. [Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial.](#) Heller JH, Spiridigliozzi GA, Sullivan JA, Doraiswamy PM, Krishnan RR, Kishnani PS. Am J Med Genet A. 2003 Jan 15;116A(2):111-6.
14. [A combination of physical examination and ECG detects the majority of hemodynamically significant heart defects in neonates with Down syndrome.](#) Shashi V, Berry MN, Covitz W. American Journal of Medical Genetics. 2002 Jan; 108(3): 205-8.
15. [Frequency of celiac disease in individuals with Down syndrome in the United States.](#) Mackey J, Treem WR, Worley G, Boney A, Hart P, Kishnani PS. Clin Pediatr (Phila). 2001 May;40(5):249-52.
16. [Donepezil for Down's syndrome.](#) Kishnani PS, Spiridigliozzi GA, Heller JH, Sullivan JA, Doraiswamy PM, Krishnan KR. Am J Psychiatry. 2001 Jan;158(1):143.
17. [Cholinergic therapy for Down's syndrome.](#) Kishnani PS, Sullivan JA, Walter BK, Spiridigliozzi GA, Doraiswamy PM, Krishnan KR. Lancet. 1999 Mar 27;353(9158):1064-5.